International Pain and Spine Intervention Society (IPSIS)’s Post

#Slack DMs can make it hard to track requests and measure workload impact of your #ITHelpdesk. Hear how Cohere, Xilio Therapeutics and Foqal took back control in 4/17 webinar https://hubs.ly/Q02pyQ0V0

#Slack DMs can make it hard to track requests and measure workload impact of your #ITHelpdesk. Hear how Cohere, Xilio Therapeutics and Foqal took back control 4/17 webinar https://hubs.li/Q02pyTc90

Last week, Argenica Therapeutics lodged our Appendix 4C Quarterly Cashflow Report for the 12-month period ended 30 June 2024. One key highlight from the report was the progress made in our Phase 2 Clinical Trial. Here is an overview of the highlight Access the full report here ➡️ https://bit.ly/4ftygiq #ASX #AGN #investorupdate #stroke #clinicaltrial

While we have witnessed digital capabilities navigating the pharma through evolving landscape, the question in the realm of CGT remains - how much closer are we to demonstrating value using the universal language of data? Join senior leader from Sumitomo Pharma America, Microvascular Therapeutics, Mustang Bio and Bayer next month, to explore their visions on key trends shaping the future of CGT clinical development: https://bit.ly/3OkH4Ly

While we have witnessed digital capabilities navigating the pharma through evolving landscape, the question in the realm of CGT remains - how much closer are we to demonstrating value using the universal language of data? Join senior leader from Sumitomo Pharma America, Microvascular Therapeutics, Mustang Bio and Bayer next month, to explore their visions on key trends shaping the future of CGT clinical development: https://bit.ly/3OkH4Ly

4/17 Webinar: How to take back control of your #ITHelpdesk from #Slack DMs. Cohere, Xilio Therapeutics, Foqal share experience. Register here: https://hubs.ly/Q02pyRpN0

It’s so rewarding knowing that with your work, you can make a difference in the lives of people living with a rare disease. With our marketing efforts, we aim to increase awareness of the disease, improve diagnosis, and ensure patients in need have access to this first available treatment in Europe. Because every single life counts. #rewards #marketing #healthcare #rarediseases #diagnosis

As we navigate the aftermath of COVID-19, the IPPS report outlines actions for all sectors to increase preparedness, and renew focus in 2024 on diagnostics, therapeutics, regulatory harmonisation and sustainable clinical trials. Explore the insights here: https://lnkd.in/e5q2SjTA #FIND#Diagnostics#IVD#IPPS

The interim report for the third quarter is now available! Stayble Therapeutics has published its interim report for the third quarter of 2023. Comment from our CEO, Andreas Gerward: “We at Stayble aim for every shareholder to clearly understand the differences between our two different indications. From now on, we will carefully analyze the data from the phase 2b study. We plan to update the market with more detailed information on all the data and explain why our belief in the potential of the herniated disc project still remains.” Explore the full report by following the link: https://lnkd.in/emAFbjw5  

If you missed the December 1st webinar from ReCode Therapeutics, the recording is now available at the link below! Watch today to learn about the clinical trials process. https://lnkd.in/gnZ5fKY6